Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APRE |
---|---|---|
09:32 ET | 118 | 5.02 |
09:54 ET | 100 | 5.37 |
09:57 ET | 400 | 5.265 |
09:59 ET | 600 | 5.34 |
10:14 ET | 500 | 5.46 |
10:28 ET | 160 | 5.4599 |
11:09 ET | 300 | 5.39 |
11:13 ET | 500 | 5.39 |
11:42 ET | 3055 | 5.3746 |
12:20 ET | 1656 | 5.35 |
01:06 ET | 100 | 5.35 |
03:20 ET | 386 | 5.355 |
03:27 ET | 200 | 5.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aprea Therapeutics Inc | 28.1M | -1.3x | --- |
IGC Pharma Inc | 29.2M | -1.7x | --- |
Pluri Inc | 26.6M | -1.0x | --- |
Enlivex Therapeutics Ltd | 27.9M | -0.9x | --- |
BioVie Inc | 27.8M | -0.4x | --- |
Oncternal Therapeutics Inc | 25.3M | -0.6x | --- |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.1M |
---|---|
Revenue (TTM) | $583.2K |
Shares Outstanding | 5.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.07 |
EPS | $-4.00 |
Book Value | $4.89 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 48.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,652.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.